Depot haloperidol treatment in outpatients with schizophrenia on monotherapy: Impact of CYP2D6 polymorphism on pharmacokinetics and treatment outcome

Therapeutic Drug Monitoring

Volumn 29, Issue 4, 2007, Pages 417-422

  Panagiotidis, Georgios ^a   Arthur, Holger W ^a   Lindh, Jonatan D ^a   Dahl, Marja Liisa ^b   Sjöqvist, Folke ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

CYP2D6; Genotype; Haloperidol; Metabolism; Pharmacokinetics

Indexed keywords

CYTOCHROME P450 2D6; HALOPERIDOL;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG BLOOD LEVEL; DRUG SAFETY; EXTRAPYRAMIDAL SYMPTOM; FEMALE; GENE FUNCTION; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; MALE; MENTAL PATIENT; MONOTHERAPY; MULTIPLE LINEAR REGRESSION ANALYSIS; MUTATIONAL ANALYSIS; OUTPATIENT; PARKINSONISM; PHARMACOGENETICS; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; SCHIZOPHRENIA; STEADY STATE; TREATMENT OUTCOME;

ADULT; ALLELES; ANTIPSYCHOTIC AGENTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOCHROME P-450 CYP2D6; DELAYED-ACTION PREPARATIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GENOTYPE; HALOPERIDOL; HUMANS; INJECTIONS, INTRAMUSCULAR; MALE; MIDDLE AGED; OUTPATIENTS; POLYMORPHISM, GENETIC; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 34547697228     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/FTD.0b013e31811f394d     Document Type: Article

References (31)

1. Van de Vijver D, Roos R, Jansen P, et al. Antipsychotics and Parkinson's disease: association with disease and drug choice during the first 5 years of antiparkinsonian drug treatment. Eur J Clin Pharmacol. 2002;58:157-161.
2. Dahl-Puustinen ML, Liden A, Alm C, et al. Disposition of perphenazine is related to polymorphic debrisoquin hydroxylation in human beings. Clin Pharmacol Ther. 1989;46:78-81.
3. Dahl ML, Ekqvist B, Widén J, et al. Disposition of the neuroleptic zuclopenthixol cosegregates with the polymorphic hydroxylation of debrisoquine in humans. Acta Psychiatr Scand. 1991;84:99-102.
4. Von Bahr C, Movin G, Nordin C, et al. Plasma levels of thioridazine and metabolites are influenced by the debrisoquine hydroxylation phenotype. Clin Pharmacol Ther. 1991;49:234-240.
5. Llerena A, Alm C, Dahl ML, et al. Haloperidol disposition is dependent on debrisoquine hydroxylation phenotype. Ther Drug Monit. 1992 a;14:92-97.
6. Llerena A, Dahl ML, Ekqvist B, et al. Haloperidol disposition is dependent on debrisoquine hydroxylation phenotype: increased plasma levels of the reduced metabolite in poor metabolizers. Ther Drug Monit. 1992 b;14:261-264.
7. Roh HK, Chung JY, Oh DY, et al. Plasma concentrations of haloperidol are related to CYP2D6 genotype at low, but not high doses of haloperidol in Korean schizophrenic patients. Br J Clin Pharmacol. 2001;52:265-271.
8. http://www.imm.ki.se/CYPalleles/CYP2D6.htm. Accessed October 10, 2006.
9. Dahl ML. Cytochrome p450 phenotyping/genotyping in patients receiving antipsychotics: useful aid to prescribing? Clin Pharmacokinet. 2002;41:453-470.
10. Cascorbi I. Pharmacogenetics of Cytochrome P450 2D6: genetic background and clinical implication. Eur J Clin Invest. 2003;33(Suppl 2):17-22.
11. Johansson J, Lundqvist E, Bertilsson L, et al. Inherited amplification of an active gene in the cytochrome P450 2D locus as a cause of ultrarapid metabolism of debrisoquine. Proc Natl Acad Sci U S A. 1993;90:11825-11829.
12. Jerling M, Dahl ML, Åberg-Wistedt A, et al. The CYP2D6 genotype predicts the oral clearance of the neuroleptic agents perphenazine and zuclopenthixol. Cli Pharmacol Ther. 1996;59:423-428.
13. Linnet K, Wiborg O. Steady-state serum concentrations of the neuroleptic perphenazine in relation to CYP2D6 genetic polymorphism. Clin Pharmacol Ther. 1996;60:41-47.
14. Scordo MG, Spina E, Facciola G, et al. Cytochrome P450 2D6 genotype and steady state plasma levels of risperidone and 9-hydroxyrisperidone. Psychopharmacology. 1999;147:300-305.
15. Berecz R, de la Rubina A, Dorado P, et al. Thioridazine steady-state plasma concentrations are influenced by tobacco smoking and CYP2D6, but not by the CYP2C9 genotype. Eur J Clin Pharmacol. 2003;59:45-50.
16. Suzuki A, Otani K, Mihara K, et al. Effects of the CYP2D6 genotype on the steady-state plasma concentrations of haloperidol and reduced haloperidol in Japanese schizophrenic patients. Pharmacogenetics. 1997;7:415-418.
17. Brockmöller J, Kirchheiner J, Schmider J, et al. The impact of the CYP2D6 polymorphism on haloperidol pharmacokinetics and on the outcome of haloperidol treatment. Clin Pharmacol Ther. 2002:438-452.
18. Arthur H, Dahl ML, Siwers B, et al. Polymorphic drug metabolism in schizophrenic patients with tardive dyskinesia. J Clin Psychopharmacol. 1995;15:211-216.
19. Lohmann PL, Bagli M, Krauss H, et al. CYP2D6 polymorphism and tardive dyskinesia in schizophrenic patients. Pharmacopsychiatry. 2003;36:73-78.
20. Plesnicar BK, Zalar B, Breskvar K, et al. The influence of the CYP2D6 polymorphism on psychopathological and extrapyramidal symptoms in the patients on long-term antipsychotic treatment. J Psychopharmacol. 2006;20:829-833.
21. Kawanishi C, Lundgren S, Ågren H, et al. Increased incidence of CYP2D6 gene duplication in patients with persistent mood disorders: ultrarapid metabolism of antidepressants as a cause of nonresponse. A pilot study. Eur J Clin Pharmacol. 2004;59:803-807.
22. Garavan J, Browne S, Gervin M, et al. Compliance with neuroleptic medication in outpatients with schizophrenia; relationship to subjective response to neuroleptics; attitudes to medication and insight. Compr Psychiatry. 1998;39:215-219.
23. Castle D, Morgan V, Jablensky A. Antipsychotic use in Australia: the patients' perspective. Aust N Z J Psychiatry. 2002;36:633-641.
24. Svensk Läkemedelsstatistik/IMS Health. "Swedish drug statistics." http://www.apoteket.se. Accessed October 10, 2006.
25. Diagnostic and Statistical Manual of Mental Disorders, ed 4. Washington, DC: American Psychiatric Association; 1994.
26. Kay SR, Fiszbein A, Opler LA. The Positive and Negative Syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13:261-276.
27. Chouinard G, Margolese HC. Manual for the Extrapyramidal Symptom Rating Scale (ESRS). Schizophr Res. 2005;76:247-265; Erratum, Schizophr Res. 2006;85:305.
28. Dahl ML, Johansson I, Palmertz MP, et al. Analysis of the CYP2D6 gene in relation to debrisoquin and desipramine hydroxylation in a Swedish population. Clin Pharmacol Ther. 1992;51:12-17.
29. Heim M, Meyer UA. Genotyping of poor metabolisers of debrisoquine by allele specific PCR amplification. Lancet. 1990;336:529-532.
30. Scordo MG, Spina E, Romeo P, et al. CYP2D6 genotype and antipsychotic-induced extrapyramidal side-effects in schizophrenic patients. Eur J Clin Pharmacol. 2000;56:679-683.
31. 2 dopamine receptor occupancy during low-dose treatment with haloperidol decanoate. Am J Psychiatry. 1995;152:173-178.